OpenLB
Open Library of Bioscience
Advanced Search
Trends in microbiology
08, 2020;28 (8): 619-632.

Chronic Immune Activation in TB/HIV Co-infection.

Riti Sharan, Allison N Bucşan, Shashank Ganatra, Mirko Paiardini, Mahesh Mohan, Smriti Mehra, Shabaana A Khader, Deepak Kaushal
Author Information
  1. Riti Sharan: Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
  2. Allison N Bucşan: Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
  3. Shashank Ganatra: Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
  4. Mirko Paiardini: Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  5. Mahesh Mohan: Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
  6. Smriti Mehra: Tulane National Primate Research Center, Tulane University School of Medicine, Covington, LA 70433, USA.
  7. Shabaana A Khader: Department of Molecular Microbiology, Washington University in St Louis School of Medicine, St Louis, MO 63110, USA.
  8. Deepak Kaushal: Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX 78227, USA. Electronic address: dkaushal@txbiomed.org.
PMID: 32417227 DOI: 10.1016/j.tim.2020.03.015

Abstract

HIV co-infection is the most critical risk factor for the reactivation of latent tuberculosis (TB) infection (LTBI). While CD4 T cell depletion has been considered the major cause of HIV-induced reactivation of LTBI, recent work in macaques co-infected with Mycobacterium tuberculosis (Mtb)/simian immunodeficiency virus (SIV) suggests that cytopathic effects of SIV resulting in chronic immune activation and dysregulation of T cell homeostasis correlate with reactivation of LTBI. This review builds on compelling data that the reactivation of LTBI during HIV co-infection is likely to be driven by the events of HIV replication and therefore highlights the need to have optimum translational interventions directed at reactivation due to co-infection.

Keywords

Mtb SIV chronic immune activation co-infection nonhuman primates

References

  1. Cell Rep. 2019 Mar 26;26(13):3586-3599.e7 [PMID: 30917314]
  2. Eur Respir J. 2017 Jun 8;49(6): [PMID: 28596434]
  3. Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5636-44 [PMID: 27601645]
  4. Emerg Infect Dis. 2010 May;16(5):757-63 [PMID: 20409363]
  5. J Clin Invest. 2013 Feb;123(2):712-26 [PMID: 23281399]
  6. J Med Primatol. 2004 Apr;33(2):83-97 [PMID: 15061721]
  7. Clin Exp Immunol. 2001 Feb;123(2):233-8 [PMID: 11207653]
  8. AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):91-8 [PMID: 10659047]
  9. Nat Med. 2006 Dec;12(12):1365-71 [PMID: 17115046]
  10. Am J Pathol. 2015 Mar;185(3):820-33 [PMID: 25549835]
  11. J Immunol. 2016 Aug 15;197(4):1100-1110 [PMID: 27412415]
  12. J Immunol. 2007 Jun 1;178(11):6958-67 [PMID: 17513745]
  13. Pathog Immun. 2016 Spring;1(1):107-116 [PMID: 27500281]
  14. J Exp Med. 2004 Nov 15;200(10):1299-314 [PMID: 15545355]
  15. PLoS Pathog. 2010 Aug 19;6(8):e1001052 [PMID: 20808901]
  16. EBioMedicine. 2015 Apr 1;2(4):334-340 [PMID: 26114158]
  17. PLoS One. 2014 Sep 25;9(9):e108383 [PMID: 25255287]
  18. J Comp Pathol. 2015 Feb-Apr;152(2-3):217-26 [PMID: 25481611]
  19. Nature. 1991 Jun 6;351(6326):479-82 [PMID: 2046750]
  20. J Infect Dis. 2013 Jun 15;207(12):1841-9 [PMID: 23479321]
  21. Tuberculosis (Edinb). 2016 Jan;96:1-12 [PMID: 26786648]
  22. Medicine (Baltimore). 2016 Jan;95(3):e2459 [PMID: 26817879]
  23. Sci Rep. 2016 Feb 24;6:21522 [PMID: 26908312]
  24. J Neuroimmune Pharmacol. 2011 Dec;6(4):516-27 [PMID: 21830069]
  25. J Med Primatol. 2011 Aug;40(4):233-43 [PMID: 21781131]
  26. Clin Exp Immunol. 1996 Jan;103(1):30-4 [PMID: 8565282]
  27. Nature. 2014 Jul 31;511(7511):601-5 [PMID: 25043006]
  28. Front Immunol. 2019 Apr 30;10:914 [PMID: 31114576]
  29. J Clin Invest. 2019 Dec 2;129(12):5254-5260 [PMID: 31479428]
  30. J Immunol. 2007 Sep 1;179(5):3026-34 [PMID: 17709517]
  31. Mucosal Immunol. 2018 Mar;11(2):462-473 [PMID: 28745326]
  32. Lancet Respir Med. 2019 Sep;7(9):757-770 [PMID: 31416768]
  33. Hum Immunol. 2016 Dec;77(12):1264-1270 [PMID: 27521485]
  34. Adv Exp Med Biol. 2013;762:155-81 [PMID: 22975875]
  35. Antivir Ther. 2012;17(2):355-64 [PMID: 22290239]
  36. Clin Infect Dis. 2006 Apr 1;42(7):1040-7 [PMID: 16511773]
  37. Mucosal Immunol. 2016 Nov;9(6):1528-1536 [PMID: 26838048]
  38. Top Antivir Med. 2013 Sep-Oct;21(4):128-32 [PMID: 24225078]
  39. J Immunol. 2014 Mar 15;192(6):2821-9 [PMID: 24534529]
  40. Lancet Respir Med. 2018 Apr;6(4):287-298 [PMID: 29595510]
  41. J Int AIDS Soc. 2016 Jan 12;19(1):20714 [PMID: 26765347]
  42. PLoS One. 2015 Jul 24;10(7):e0133924 [PMID: 26208109]
  43. Biochem Biophys Res Commun. 2006 Oct 13;349(1):353-9 [PMID: 16935261]
  44. Curr Opin Virol. 2016 Aug;19:37-44 [PMID: 27447445]
  45. AIDS. 2006 Jan 9;20(2):F1-7 [PMID: 16511406]
  46. Sci Rep. 2019 Feb 6;9(1):1502 [PMID: 30728405]
  47. J Infect Dis. 2013 Apr;207(7):1115-27 [PMID: 23255564]
  48. Nat Med. 2016 May;22(5):531-8 [PMID: 27043495]
  49. Cell Microbiol. 2015 Aug;17(8):1085-97 [PMID: 25653138]
  50. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):325-31 [PMID: 9342251]
  51. J Virol. 2010 Aug;84(15):7886-91 [PMID: 20484518]
  52. Vaccine. 2015 Oct 13;33(42):5715-5722 [PMID: 26192357]
  53. Virology. 2007 Sep 1;365(2):356-68 [PMID: 17490699]
  54. AIDS Res Hum Retroviruses. 2006 Jan;22(1):45-51 [PMID: 16438645]
  55. Am J Pathol. 2017 Dec;187(12):2811-2820 [PMID: 28935575]
  56. Infect Immun. 2018 Nov 20;86(12): [PMID: 30224552]
  57. Curr Opin HIV AIDS. 2019 Jan;14(1):46-54 [PMID: 30346311]
  58. PLoS One. 2010 Aug 31;5(8):e12266 [PMID: 20824205]
  59. Nat Commun. 2015 Oct 13;6:8533 [PMID: 26460802]
  60. Blood. 2009 Oct 1;114(14):2917-25 [PMID: 19383966]
  61. Nature. 2005 Apr 28;434(7037):1093-7 [PMID: 15793563]
  62. Tuberculosis (Edinb). 2016 Jan;96:141-9 [PMID: 26723465]
  63. J Infect. 2018 Jan;76(1):44-54 [PMID: 29061336]
  64. Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10693-7 [PMID: 7479867]
  65. Lancet Glob Health. 2015 Jan;3(1):e10-2 [PMID: 25539957]
  66. J Virol. 2013 May;87(9):5151-60 [PMID: 23449790]
  67. PLoS One. 2010 Mar 10;5(3):e9611 [PMID: 20224771]
  68. Clin Vaccine Immunol. 2017 Jan 5;24(1): [PMID: 27655885]
  69. PLoS One. 2018 Mar 19;13(3):e0194675 [PMID: 29554144]
  70. Am J Respir Crit Care Med. 2016 Jun 1;193(11):1307-10 [PMID: 27248590]
  71. Nat Med. 2017 Nov;23(11):1277-1286 [PMID: 29035370]
  72. Vaccine. 2009 Jul 30;27(35):4857-66 [PMID: 19520196]
  73. Trends Microbiol. 2013 Jan;21(1):6-13 [PMID: 23062765]
  74. J Virol. 2011 Jun;85(12):5929-39 [PMID: 21471240]
  75. Mucosal Immunol. 2015 Jul;8(4):760-72 [PMID: 25407519]
  76. Am J Respir Crit Care Med. 2015 May 15;191(10):1185-96 [PMID: 25730547]
  77. Front Immunol. 2018 Mar 27;9:643 [PMID: 29636755]
  78. N Engl J Med. 2018 Jul 12;379(2):138-149 [PMID: 29996082]
  79. Tuberculosis (Edinb). 2016 Jan;96:131-40 [PMID: 26631832]
  80. BMJ Open. 2018 Feb 6;8(2):e016961 [PMID: 29437750]
  81. J Infect Dis. 2018 May 25;217(12):1865-1874 [PMID: 29432596]
  82. Am J Epidemiol. 2014 Sep 1;180(5):556-7 [PMID: 25122585]
  83. Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231 [PMID: 30092143]
  84. PLoS One. 2013 Aug 05;8(8):e70630 [PMID: 23940611]
  85. PLoS Pathog. 2014 Oct 30;10(10):e1004467 [PMID: 25356757]
  86. Eur Respir J. 2009 May;33(5):956-73 [PMID: 19407047]
  87. Infect Immun. 2018 Jan 22;86(2): [PMID: 28947646]
  88. Am J Respir Cell Mol Biol. 2017 May;56(5):637-647 [PMID: 28135421]
  89. PLoS One. 2012;7(10):e46191 [PMID: 23056259]
  90. Am J Respir Cell Mol Biol. 2015 Jun;52(6):708-16 [PMID: 25322074]
  91. Am J Respir Crit Care Med. 2010 Jan 1;181(1):80-6 [PMID: 19833824]
  92. Oral Dis. 2016 Apr;22 Suppl 1:53-60 [PMID: 27109273]
  93. Pathol Res Pract. 2008;204(3):155-61 [PMID: 18096327]
  94. J Immunol. 2007 Sep 1;179(5):3035-46 [PMID: 17709518]
  95. J Clin Invest. 2009 Dec;119(12):3556-72 [PMID: 19959874]
  96. Ethiop J Health Sci. 2019 Jan;29(1):859-868 [PMID: 30700953]
  97. PLoS Pathog. 2012;8(4):e1002620 [PMID: 22496647]
  98. Scand J Immunol. 2011 Mar;73(3):234-42 [PMID: 21204895]
  99. PLoS Pathog. 2015 May 21;11(5):e1004917 [PMID: 25996154]
  100. AIDS. 2006 Aug 1;20(12):1605-12 [PMID: 16868441]
  101. Clin Exp Immunol. 2000 Dec;122(3):350-7 [PMID: 11122240]
  102. J Interferon Cytokine Res. 2019 Jun;39(6):355-363 [PMID: 30939065]
  103. J Infect. 2013 Jan;66(1):57-66 [PMID: 23046968]
  104. J Infect Dis. 2010 Aug 15;202(4):533-41 [PMID: 20617900]
  105. J Virol. 2008 Feb;82(3):1175-84 [PMID: 18032487]
  106. J Clin Invest. 2015 Dec;125(12):4497-513 [PMID: 26551680]
  107. AIDS. 2016 Jun 19;30(10):1511-20 [PMID: 26807971]
  108. Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E62-E71 [PMID: 29255022]
  109. Lancet. 2018 Jul 28;392(10144):312-358 [PMID: 30032975]
  110. J Virol. 2019 Jul 17;93(15): [PMID: 31118264]
  111. Clin Vaccine Immunol. 2013 May;20(5):663-72 [PMID: 23446219]
  112. Int Immunol. 2006 Oct;18(10):1443-51 [PMID: 16916890]
  113. J Infect Dis. 2007 May 1;195(9):1303-10 [PMID: 17396999]
  114. J Med Primatol. 2017 Apr;46(2):59-62 [PMID: 28145571]
  115. N Engl J Med. 2011 Oct 20;365(16):1471-81 [PMID: 22010913]
  116. Int J Tuberc Lung Dis. 2015 Aug;19(8):969-78 [PMID: 26162364]

Grants

  1. R01 AI123780/NIAID NIH HHS
  2. UH3 AI122320/NIAID NIH HHS
  3. R01 AI111914/NIAID NIH HHS
  4. R01 AI123047/NIAID NIH HHS
  5. R01 DA042524/NIDA NIH HHS
  6. R01 AI134240/NIAID NIH HHS
  7. P51 OD011133/NIH HHS
  8. R01 AI111943/NIAID NIH HHS
  9. P51 OD011104/NIH HHS
  10. R01 AI138587/NIAID NIH HHS
  11. U42 OD010442/NIH HHS

MeSH Term

Animals
CD4-Positive T-Lymphocytes
Coinfection
Disease Models, Animal
HIV Infections
Humans
Latent Tuberculosis
Lymphocyte Depletion
Macaca mulatta
Mycobacterium tuberculosis
Simian Acquired Immunodeficiency Syndrome
Simian Immunodeficiency Virus
Journal Article Research Support, N.I.H., Extramural Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0reactivationco-infectionLTBIHIVSIVtuberculosisTcellMtbchronicimmuneactivationcriticalriskfactorlatentTBinfectionCD4depletionconsideredmajorcauseHIV-inducedrecentworkmacaquesco-infectedMycobacterium/simianimmunodeficiencyvirussuggestscytopathiceffectsresultingdysregulationhomeostasiscorrelatereviewbuildscompellingdatalikelydriveneventsreplicationthereforehighlightsneedoptimumtranslationalinterventionsdirecteddueChronicImmuneActivationTB/HIVCo-infectionnonhumanprimates

Similar Articles

Cited By